Children's Hospital Researchers philadelphia (CHOP) Aiming to expand patient access to treatment
Mountain View, California, December 3, 2024 /PRNewswire/ — Turn Biotechnologies, a cell rejuvenation and recovery company developing new mRNA medicines for untreatable age-related conditions, uses epigenetic reprogramming to rejuvenate bone marrow stem cells. We published the latest research evaluating the effectiveness of
This study, funded by the Methuselah Foundation, is the first to evaluate the use of TurnBio's proprietary RNA-based ERA™ therapy to rejuvenate bone marrow function to improve the quality of donor cells used in stem cell transplants. It's research. Healthy bone marrow releases blood cells into the bloodstream. As adults age, the bone marrow produces fewer disease-fighting B and T cells and other products that help reduce inflammation throughout the body. Aging stem cells also collect DNA changes known as clonal hematopoiesis that serve as precursors to the development of leukemia.
“Multiple studies on clinical bone marrow transplant outcomes show that patients who receive donor stem cells from younger donors are at greater risk of graft dysfunction and donor clonal hematopoiesis due to more permanent correction of underlying blood and immune defects. “It's been shown to have good outcomes because it's so low,” he said. timothy olsonMD, PhD, principal investigator of this study and medical director of blood and bone marrow transplantation and co-chief of the cell therapy and transplantation section at Children's Hospital philadelphia (chop). “We hope this study shows that epigenetic reprogramming can help make bone marrow transplants more effective and more accessible to patients.”
Rejuvenating old bone marrow cells can improve the body's ability to fight disease, accelerate wound healing, improve the oxygen-carrying capacity of blood cells, and increase the success rate of donor-to-patient transplants. This could allow older donors to be used for transplants.
A transplant replaces a patient's diseased blood-forming cells with healthy cells. This procedure is used to treat certain types of cancer, blood disorders, and autoimmune diseases. Of the 50,000 bone marrow transplants performed annually worldwide, nearly half are performed in the following regions: US.
The Methuselah Foundation is interested in increasing survival rates for bone marrow transplant and gene therapy patients. Current survival rates for patients with non-malignant disease are greater than 70% for matched sibling donors and greater than 36% for unrelated donors.
Researchers aim to make these intensive treatments safer and more effective by rejuvenating donor stem cells. Additionally, with the increasing use of gene therapy and gene editing, the ability to rejuvenate stem cells during these processes could make one-time treatments safer and more effective.
“We believe this study confirms that epigenetic reprogramming can effectively rejuvenate bone marrow cells and restore youthful performance, which has the potential to extend healthy lifespan in humans. '' he said. david goebelCo-founder and CEO of the Methuselah Foundation, the world's first biomedical nonprofit organization focused on human longevity.
The year-long study will measure the effectiveness of Turn's ERA solution by treating mouse blood progenitor cells and transplanting those cells into irradiated mice of the same genetic background.
“This research demonstrates how we are leveraging our science to go beyond individual treatments to create solutions for a variety of diseases, and is an important addition to TurnBio. “This is a milestone. We are optimistic that this study will validate the dramatic impact of epigenetic reprogramming in improving human healthspan.” Anja KramerCEO of TurnBio. “We have repeatedly demonstrated that ERA treatment can safely rejuvenate human cells. This is an opportunity to make theory a reality.”
The research will be carried out by: Timothy S. OlsonMD, PhD, Deputy Section Chief of the Cell Therapy and Transplant Program at Children's Hospital philadelphia (CHOP), with support from Turn Bio Scientific Advisors: Joseph Hai Oved, MD, Leader of the Primary Immunodeficiency and Immune Dysregulation Program at Memorial Sloan Kettering Cancer Center new yorkand Kevin J. Curran, MD, director of the Immune Effector Cell Program at Memorial Sloan Kettering Cancer Center.
About Turn Biotechnologies
Turn Bio is a preclinical-stage company focused on tissue repair at the cellular level and the development of innovative drug delivery systems. The company's proprietary mRNA-based ERA™ technology combats the effects of aging on the epigenome and restores optimal gene expression. This restores the cells' ability to prevent or treat disease and heal or regenerate tissue. Helps fight incurable chronic diseases. The eTurna™ delivery platform uses proprietary formulations to precisely deliver cargo to specific organs, tissues, and cell types.
The company has completed preclinical studies on tailored therapies for dermatology and immunology indications, and is developing treatments for ophthalmology, osteoarthritis, and muscular system. For more information, see www.turn.bio.
For more information, please contact us:
Jim MartinezLight Story Group
[email protected] or (312) 543-9026
SOURCE Turn Biotechnologies, Inc.
I want company news Have you been featured on PRNEWSWIRE.COM?
Over 440,000
newsroom and
influencer
9k+
digital media
outlet
Over 270,000
journalist
opt-in
